This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): nilvadipine
Description: Events related to the use of Nivadil as a treatment for Alzheimer's Disease can be found under the generic name Nilvadipine.
Nivadil is a dihydropyridine type calcium channel blocker is approved for the treatment of hypertension in Japan and Europe. Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Although the mechanism of this effect is not known, nilvadipine has been shown to have beneficial effects, such as counteracting dysregulation of calcium homeostasis, vasoconstriction and neuronal apoptosis associated with amyloid peptide, and moreover is a more efficient free-radical scavenger than other calcium channel blockers. In addition, Archer has data suggesting that nilvadipine and related compounds can have direct effect on lowering soluble amyloid levels independently of their impact on calcium channels.
Deal Structure: Nivadil was originally developed by Fujisawa. In May 2004, Fujisawa and Yamanouchi finalized a merger agreement to form Astellas.
The patent on the original composition of Nivadil expired, and Archer Pharmaceuticals, a commercial spinoff of the Roskamp Institute, now owns intellectual property rights to developing the drug as a treatment for Alzheimer's Disease.
Pink Sheet Fujisawa
Additional information available to subscribers only: